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Abstract
Background: Multiple small drilling for core decompression is widely used to preserve the femoral head in patients
with avascular necrosis of the femoral head (ANFH). Nevertheless, the clinical outcome remains controversial.
Simvastatin has been demonstrated to promote bone formation and reduce bone adsorption. The purpose of
this study was to determine whether simvastatin enhanced the effect of multiple decompressions in preventing
progression of ANFH and to identify independent risk factors associated with poor results.
Methods: We retrospectively analyzed 58 hips in 36 patients, with a follow-up of 36 months. 20 patients (32 hips)
underwent multiple drilling combined with simvastatin treatment (SIM group); 16 patients (26 hips) underwent
multiple drilling alone (MD group). We defined clinical failure as a requirement for subsequent hip surgery or
Harris Hip Score < 75. New occurrence of collapse or increased collapse > 2 mm on plain radiographs was
defined as radiological failure.
Results: Successful clinical results were achieved in 27 of 32 hips (84 %) in the SIM group compared with 15 of 26
hips (58 %) in the MD group (OR = 0.2, CI (0.1, 0.6.), P = 0.032). Successful radiological results were achieved in 27 of
32 hips (84 %) in the SIM group and in 16 of 26 hips (61.5 %) in the MD group (P = 0.048). Body mass index, disease
stage and location of lesion were independent prognostic factors for overall survival.
Conclusions: We believe that simvastatin could enhance the effects of multiple decompressions in preventing
progression of ANFH and reducing the risk of femoral head collapse.
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Background
Avascular necrosis of the femoral head (ANFH) is a
common cause of hip disability in relatively young, active
people between 20 and 40 years of age. It may progress to
collapse of the femoral head if left untreated [1] and 80 %
of these patients will require total hip arthroplasty (THA)
[2]. Preservation of the femoral head is the ultimate goal
in the treatment of ANFH [3]. Although many treatment
methods for early stage ANFH, including electrical stimu-
lation, core decompression, rotational osteotomy and
nonvascularized and vascularized bone grafting, have been
proposed based on patient age, symptoms, stage, and/or
medical status, the orthopedic community has not yet
adopted a uniform treatment algorithm [4].
Core decompression, which is thought to decrease
intramedullary pressure, encourage revascularization and
relieve pain, is a widely accepted procedure for early stage
ANFH [5, 6]. Although core decompression and core
decompression in combination with bone graft, bone
marrow injection, platelet-rich plasma injection or mesen-
chymal stem cell injection have achieved excellent clinical
outcomes in the treatment of ANFH [2, 5, 7, 8], some
reports note complication rates as high as 10–15 %
[8–11]. Seeking a minimally invasive, safe and effective
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treatment for ANFH, Kim et al. proposed the use of mul-
tiple small drilling for core decompression at the annual
Association Internationale de Recherche sur la Circulation
Osseuse (ARCO) meeting in 2003. They reported a lower
rate of collapse (14.3 %) compared with traditional core
decompression methods (45 %) 3 years after surgery [12].
Statins have been demonstrated to reduce the risk of
corticosteroid-induced ANFH through improving distur-
bances of lipid metabolism [13–16]. In addition, it has
been reported that statins can increase the expression of
bone morphogenetic protein 2 (BMP-2) mRNA in osteo-
blasts, promote bone formation [17, 18] and decrease
the formation and activity of osteoclasts, inhibiting bone
resorption [19, 20]. Clinical studies have discovered that
statins can reduce fracture risk [21], increase bone mineral
density [22] and promote the expression of biochemical
markers of bone metabolism to serve as a tool for the
diagnosis of osteoporosis [23].
The purpose of the present study was to: (1) determine
whether simvastatin can enhance the effects of multiple
decompressions in preventing the progression of ANFH
and reducing the risk of femoral head collapse; and (2)
identify independent risk factors associated with poor
results.
Methods
Multiple small-diameter drilling was performed by one of
us (Zhenfeng Yuan) between April 2011 and June 2012 in
39 patients (64 hips) at the same institution for the treat-
ment of non-traumatic osteonecrosis of the femoral head.
Of these patients, 21 (34 hips) received simvastatin after
the procedure. Eighteen patients (30 hips) who refused
subsequent treatment with simvastatin were taken as con-
trols. Patients in the MD group underwent core decom-
pression with multiple small-diameter drilling. Patients in
the SIM group underwent multiple drilling combined with
oral simvastatin, 20 mg per day for 12 months beginning
on the day after the drilling procedure. In the MD group,
two patients (four hips) were lost to follow-up; therefore,
16 patients (26 hips) were available for study. In the SIM
group, one patient (two hips) was lost to follow-up; there-
fore, 20 patients (32 hips) were available for study (Fig. 1).
Observations were truncated 36 months postoperatively
to permit statistical comparison between the two groups.
This study was approved by the ethics committee of
Liaocheng People’s Hospital and informed consent was
obtained from all individual participants included in the
study.
Osteonecrosis of the femoral head was diagnosed if
magnetic resonance imaging (MRI) (coronal and sagittal)
revealed the following: belt-shaped or circular low inten-
sity signals surrounded by high intensity signals in the
outer area on short tau inversion; or a high intensity area
surrounded by belt-shaped or circular low intensity signals
within the femoral head on T1-weighted images [24]. The
patients were classified according to the ARCO system
[25]. Patients were eligible for inclusion in the study if
they were older than 18 years, had hip pain and had
ARCO stage I, II or IIIA ANFH. Patients were excluded
from the study if they had ARCO stage IIIB, IIIC or IV
ANFH. The procedure was not performed on patients
older than 60 years.
The largest anteroposterior diameter of the head (R),
the longest anteroposterior length of the necrotic lesion
Fig. 1 Flow diagram of patient selection. ANFH, avascular necrosis of femoral head
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(A) and the longest mediolateral length of the necrotic
lesion (B) were measured on axial slices on MRI. The
extent of the necrotic portion was calculated by the
equation: percentage of necrotic lesion = {(A × B)/R2} × 100.
This method has a more acceptable accuracy and is
reasonably repeatable compared with other methods
[26]. All hips were assessed using this method, with
necrotic portions greater than 30 % considered large
lesions, 15–30 % medium lesions and less than 15 %
small lesions. The location of the necrotic lesion was
classified as A, B, C1 or C2 according to the classification
developed by the Specific Disease Investigation Commit-
tee under the auspices of the Japanese Ministry of Health,
Labor and Welfare [27]. Three experienced radiologists
reviewed all MRI scans and plain radiographs together in
a blinded fashion.
Before the procedure, details of the patient’s age, gen-
der and body mass index (BMI), duration of symptoms,
cause of ANFH, unilateral or bilateral involvement,
ARCO stage, lesion size, location of lesion, Harris Hip
Score (HHS) and visual analog scale (VAS) pain score
were recorded (Table 1).
Patients were followed-up 1, 3, 6, 9, 12, 24 and
36 months after the procedure. In addition, they re-
ceived a follow-up visit whenever they were unwell.
Follow-up took the form of outpatient visits. Examina-
tions included joint pain, function and range of motion.
HHS and VAS pain score were recorded. Plain radio-
graphs (anteroposterior and frog lateral view) and MRI
scans of both hips were obtained at scheduled follow-up
times. The primary outcomes of the study were clinical
and radiological failure. Clinical failure was defined as
HHS < 75 points or a requirement for subsequent hip
surgery such as bone grafting, osteotomy or hip replace-
ment. New occurrence of collapse or increased collapse
of greater than 2 mm on plain radiographs during
follow-up was defined as radiological failure [28, 29].
For the drilling procedure, patients were placed in the
supine position on a fracture table. A C-arm fluoroscope
was draped with a sterile sleeve and positioned over the
hip region to enable an anteroposterior view. After the
position of the femoral head had been marked and the
hip draped, a 3.0 mm Steinman pin was inserted percu-
taneously under fluoroscopic guidance. The pin was
inserted into the femoral head at the site of the lesion.
Anteroposterior and lateral fluoroscopic views were ne-
cessary while advancing the pin to ensure that it
remained in the medullary canal of the femoral neck.
Depending on lesion size, each femoral head was drilled
three to six times. The wound was closed using a simple
bandage without suture.
Patients who had undergone unilateral drilling were
advised to use two crutches when walking for 6 weeks
after the procedure. Two crutches when walking for
Table 1 Baseline patient characteristics
Characteristic Total SIM Group MD Group P value
Sex 0.479
Men 26 (72) 13 (65) 13 (81)
Women 10 (28) 7 (35) 3 (19)
Age (years)
Mean 41.6 ± 1.1 39.1 ± 1.4 44.7 ± 1.6 0.010
Median 42 (37.8–48) 40 (36–44.5) 45 (41.8–49) 0.003a
BMI (kg/m2)
Mean 25.6 ± 0.3 25.6 ± 0.4 25.6 ± 0.6 0.958




3 (1–6.5) 3 (1.13–8) 2.5 (1–5.25) 0.354
Laterality 0.878
Unilateral 14 (39) 8 (40) 6 (37)
Bilateral 22 (61) 12 (60) 10 (63)




Steroids 6 (10) 3 (9) 3 (11)
Alcohol 24 (41) 15 (47) 9 (35)
Idiopathic 28 ( ) 14 (44) 14 (54)
ARCO stage 0.108b
I 10 (17) 3 (9) 7 (27)
II a 2 (3) 1 (3) 1 (4)
II b 12 (21) 10 (32) 2 (8)
II c 29 (50) 16 (50) 13 (50)
IIIa 5 (9) 2 (6) 3 (11)
Lesion size 0.021b
Small 8 (14) 2 (6) 6 (23)
Medium 13 (22) 11 (34) 2 (8)




A 2 (3) 2 (6) 0 (0)
B 26 (45) 14 (44) 12 (46)
C1 15 (26) 8 (25) 7 (27)
C2 15 (26) 8 (25) 7 (27)
Hydrarthrosis 0.985
Yes 20 (34) 11 (34) 9 (25)
No 38 (66) 21 (66) 17 (75)
VAS 6.1 ± 1.2 6.2 ± 1.4 6.0 ± 1.1 0.546
HSS score 66 ± 5.2 65 ± 5.7 68 ± 4.5 0.767
aDetermined with the Mann–Whitney U test
bDetermined with the Fisher exact test
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12 weeks were advised for patients who had undergone a
bilateral procedure. Patients were allowed to engage in
physical activities and sports 12 months after surgery. No
further rehabilitation program was implemented [28].
Statistical analysis of the data was performed using SPSS
version 18.0 for Windows (IBM, Armonk, NY, USA).
Baseline characteristics were presented using descriptive
statistics. The chi-square test was used to compare
nominal data. The t-test or Mann–Whitney U test was
used to compare metric data. Univariate analyses were
performed using the chi-square test. Variables with a
P value of less than 0.10 on univariate analysis were
entered into multivariate analysis. Causes of ANFH were
also entered into multivariate analysis. Multivariate ana-
lysis was performed using a logistic proportional hazards
regression model. Because of the multicollinearity be-
tween ARCO stage and lesion size, models were fitted
using the forward conditional procedure. All statistical
assessments were two-sided and evaluated at the 0.05 level
of statistical significance.
Results
Detailed baseline patient characteristics are shown in
Table 1. Patients in the SIM group were younger (mean
age 40 years, range 36–44.5) than those in the MD group
(mean age 45 years, range 41.8–49) (P = 0.003). There
were more patients with medium or large necrotic lesions
in the SIM group than in the MD group (P = 0.021).
At 36 months follow-up, the proportion of successful
clinical results was significantly higher in the SIM group
compared with the MD group (P = 0.024). Successful
clinical results were achieved in 27 of 32 hips (84 %) in
the SIM group (Fig. 2). Of the five hips (16 %) that were
considered clinical failures, two underwent THA because
of secondary degenerative arthritis 18 months and
26 months after the drilling procedure; the other three
had not undergone any further reconstructive procedures
at the time of the last follow-up visit. In the MD group,
successful clinical results were achieved in 15 of 26 hips
(58 %). Of those that were clinical failures, seven hips
underwent THA because of secondary degenerative
Fig. 2 Representative radiographs from SIM group. a Preoperative; b–f 3, 9, 12, 24 and 36 months postoperatively
Yin et al. BMC Musculoskeletal Disorders  (2016) 17:344 Page 4 of 8
arthritis at a mean of 14 months (range 6–26) after the
procedure, one underwent vascularized fibular grafting at
15 months and the remaining three had not undergone
any further reconstructive procedures at the last follow-
up. The SIM group had a better radiological outcome than
the MD group (P = 0.048). Successful radiological results
were achieved in 27 of 32 hips (84 %) in the SIM group
and in 16 hips (61.5 %) in the MD group (Table 2).
There was a significant difference between the preope-
rative and last follow-up HHS in both groups and a
significant difference was observed between the groups in
the last follow-up HHS (88.6 ± 7.3 vs 79.4 ± 5.3, P = 0.034).
A significant difference was observed between the SIM
group (2.4 ± 0.8) and the MD group (3.6 ± 0.6) in the last
follow-up VAS score (P = 0.014).
The procedure was a clinical success in nine of the 10
stage I hips (90 %), both stage IIa (100 %), all 12 stage
IIb (100 %), 18 of the 29 stage IIc (62.1 %) and one of
the five stage IIIa (20 %). When the hips were divided
into earlier stage (ARCO stage I, IIa or IIb) and later
stage (ARCO stage IIc or IIIa), 23 of the 24 (96 %)
earlier stage hips had successful clinical results compared
with 19 of the 34 (56 %) later stage hips (P = 0.001)
(Table 2). When the hips were stratified by lesion size, all
(100 %) hips with a small or medium necrotic lesion had
successful clinical results compared with only 21 of the 37
(57 %) hips with a large lesion (P = 0.007) (Table 2).
Among hips (52) with non-corticosteroid-induced ANFH,
24 of the 29 (82.8 %) hips in the SIM group had successful
clinical results compared with 13 of the 26 (50 %) hips in
the MD group (P = 0.038) (Table 2).
On univariate analysis, lesions located medially, low
BMI and no hydrarthrosis were associated with signifi-
cantly better clinical outcome (P = 0.029, P = 0.019 and
P = 0.031) (Table 2). Treatment type, ARCO stage,
necrotic lesion size, location of lesion, BMI and hydra-
rthrosis were included in multivariate analysis. Cause of
ANFH (corticosteroids, alcohol or idiopathic) has been
considered a predictor of clinical success in many studies
[8, 29]; therefore, we also included cause of ANFH in our
multivariate analysis, although it was not a predictor of
clinical success on univariate analysis in our patient
population. On multivariate analysis, treatment type, BMI,
ARCO stage and lesion location were identified as inde-
pendent prognostic factors for overall survival (Table 3).
There were no superficial infections, deep infections,
femoral neck fractures, subtrochanteric fractures, hete-
rotopic ossifications, hematomas or other complications
associated with the procedure in either group. No patient
has simvastatin-related complications.
Discussion
To the best of our knowledge, this is the first study
comparing the beneficial effects on ANFH of systemic
simvastatin following core decompression by multiple
small-diameter drilling. Our preliminary results show that
multiple small-diameter drilling combined with systemic
simvastatin was better than multiple small-diameter dril-
ling alone.
Given the relatively young age of patients at the time of
presentation and the fact that the currently available
prostheses may not be used for a lifetime, the treatment
Table 2 Univariate analysis of prognostic factors for clinical
success rate
Total Success Failure P value
Treatment 0.024
SIM 32 27 (84) 5 (16)
MD 26 15 (58) 11 (42)
Age (years) 0.443
< 40 17 14 (82) 3 (18)
> 40 41 28 (68) 13 (32)
Sex 0.955
Men 42 31 (74) 11 (26)
Women 16 11 (69) 5 (31)
BMI (kg/m2) 0.019
< 25 29 25 (86) 4 (14)




< 3 25 18 (72) 7 (28)
> 3 33 24 (73) 9 (27)
Laterality 1.000
Unilateral 14 10 (71) 4 (29)
Bilateral 44 32 (73) 12 (27)
Cause of ANFH 0.764a
Steroids 6 5 (83) 1 (17)
Alcohol 24 18 (75) 6 (25)
Idiopathic 28 19 (68) 9 (32)
ARCO stage 0.001
I, II a, II b 24 23 (96) 1 (4)
II c,III a 34 19 (56) 15 (44)
Lesion size 0.007a
Small + Medium 21 21 (100) 0 (0)
Large 37 21 (57) 16 (43)
Lesion location 0.029
A, B 28 24 (86) 4 (14)
C1, C2 30 18 (60) 12 (40)
Hydrarthrosis 0.031
Yes 20 11 (55) 9 (45)
No 38 31 (82) 7 (18)
aDetermined with the Fisher exact test
Percentages are in parentheses
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goal for early stage ANFH is to preserve the femoral head
rather than replace it [30]. Multiple small-diameter dril-
ling has been widely employed for the treatment of ANFH
since Kim et al. proposed its use in 2003; however, its
efficacy remains controversial (Table 4), with 30–40 % of
patients suffering clinical failure [6, 28, 31]. To improve
the clinical outcome of multiple small drilling for core
decompression, several adjunctive methods have been
added following the procedure. Kang et al. administered
systemic alendronate as a femoral head-preserving method
in ANFH; the clinical success rates in patients with stage II
or stage III disease increased by 11.5 and 15.3 %, respec-
tively, at a minimum of 4 years follow-up [29]. However, in
research conducted by Lim et al., stem cell implantation
after multiple drilling did not improve the clinical outcome
compared with the conventional method of core decom-
pression (57 % vs 54.8 %) at 5-year follow-up [32]. In this
study, systemic administration of simvastatin after multiple
drilling significantly improved the overall clinical success
rate from 57.7 to 84.4 %.
Statins inhibit hydroxymethylglutaryl-coenzyme A re-
ductase, one of the rate-limiting enzymes of the mevalo-
nate pathway, and are widely used for the treatment of
hyperlipemia. Recently, statins have been demonstrated
to be effective for the prophylaxis of corticosteroid-
induced ANFH through counteracting the effects of cor-
ticosteroid-induced adipogenesis in bone stem cells and
systemic changes in lipid metabolism [14, 16, 33, 34].
However, until now it was unknown whether statins
can improve the clinical outcome in non-corticosteroid-
induced ANFH. Our results show that simvastatin might
increase the clinical success rate in non-steroid induced
ANFH. There may be several possible mechanisms for this
effect. (1) Promotion of bone formation: By inhibiting the
mevalonate pathway and preventing the prenylation and
function of small GTPases, BMP-2 expression may be
stimulated, causing increased osteoblast expression and
differentiation and subsequent enhancement of bone
formation [35]. (2) Inhibition of bone absorption: By
suppressing cellular membrane fusion events [36] and the
RANKL signaling system [19], formation of osteoclasts
could be inhibited and, by inhibiting of the mevalonate
pathway [37], osteoclast function might be affected. (3)
Recovery of blood supply: Simvastatin could promote the
proliferation of vascular endothelial cells through stimu-
lating the release of vascular endothelial growth factor,
promoting recovery of the blood supply to the necrotic
area [38].
Several studies have demonstrated that the clinical
outcome of osteonecrosis of the femoral head is associated
with the stage of the disease [8, 28, 29]. Early disease has a
better clinical outcome. In agreement with these studies,
we achieved excellent results in hips with earlier stage
disease. Our results confirm that BMI can serve as a
valuable parameter for the evaluation of clinical outcome.
Patients with a higher BMI might have a more rapidly
Table 3 Multivariate analysis of prognostic factors for clinical
success rate






≥ 25 20.9 (1.9,234.1)
ARCO stage 0.006
I, II a, II b 1
II c,III a 32.1 (3.4,530.4)
Lesion location 0.018
A, B 1
C1, C2 17.4 (1.6,185.9)
aData in parentheses are 95 % CIs
bDetermined with logistic regression analysis
Table 4 Literature review
Study Treatment Success rate Follow-up
(months)
Overall
success rateI II III
Song et al. Multi-drilling CD 79.5 % 76.6 % 34.9 % 87 (60–134) 66.3 %
Mont et al. Multi-drilling CD 80 % 57 % - 24 (20–39) 71 %
Kang et al. Multi-drilling CD - 79 % 46.2 % 62 (49–71) 71.2 %
Lee et al. Multi-drilling CD 100 % 65 % 40 % 37.1 (24–60) 56 %
Our research Multi-drilling CD 85.7 % 56.2 % - 36 57.7 %
Omran et al. Multi-drilling CD 100 % 66.7 % - At least 24 72.7 %
Kang et al. Multi-drilling CD + alendronate - 90.5 % 61.5 % 63 (48–75) 83.6 %
Lim et al. Multi-drilling CD + stem cell - 60.8 % 42.9 % 60 53.9 %
Our research Multi-drilling CD + simvastatin 100 % 82.6 % - 36 81.5 %
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progressive form of the disease. Although several studies
have suggested that clinical outcomes are worse in pa-
tients with corticosteroid-related osteonecrosis [8, 39, 40],
in the present study the clinical outcome was unrelated to
corticosteroid use. Few hips with corticosteroid-related
osteonecrosis in this study might explain this discrepancy.
Our study has several limitations. First, this was a
retrospective study with a small number of individuals.
A large scale randomized controlled trial is essential to
evaluate the clinical efficacy of the treatment. Second,
the follow-up period was short, with observations trun-
cated 36 months postoperatively. Studies show that most
clinical failures occur within 3 years postoperatively
[8, 11], but a longer follow-up period will still be needed
in the future. Third, the simvastatin regimen was chosen
according to that used to treat osteoporosis [41]. The opti-
mal dose and duration of simvastatin treatment remain to
be determined.
Conclusion
Despite these shortcomings, from the results of our
research it seems reasonable to assume that simvastatin
can enhance the effects of multiple decompressions in
preventing the progression of ANFH and reducing the
risk of femoral head collapse. Long term results and
greater numbers of patients are needed to make defini-
tive conclusions.
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